Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2003
10/09/2003WO2003082299A1 Improved hormone replacement therapy
10/09/2003WO2003082298A1 Statin therapy for enhancing cognitive maintenance
10/09/2003WO2003082297A1 Meloxicam suppositories containing e.g. polyethylenglycol
10/09/2003WO2003082296A1 Use of methylene blue and related compounds to prevent or reverse an exaggerated hemodynamic reaction
10/09/2003WO2003082295A1 Morpholine derivatives substituted at the 2-position by a heterocyclylalkylurea group for use as ccr-3 antagonists in the treatment of inflammatory conditions
10/09/2003WO2003082293A1 Benzenesulphonate salt of a morpholine urea derivative for use as a ccr-3 antagonist in the treatment of inflammatory conditions
10/09/2003WO2003082292A1 Morpholine derivatives substituted at the 2-position by an arylalkylurea group for use as ccr-3 antagonists in the treatment of inflammatory conditions
10/09/2003WO2003082291A1 N-{´ (2s) -4- (3, 4-difluorobenzyl) morpholin-2yl!methyl} -2-{3-' (methylsulphonyl) amino! phenyl}acetamide as ccr3 antagonist for the treatment of inflammatory conditions
10/09/2003WO2003082290A1 4-(n-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors
10/09/2003WO2003082288A1 Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors
10/09/2003WO2003082287A1 Dpc 333 formulation having unique biopharmaceutical characteristics
10/09/2003WO2003082286A1 Quinoline derivatives, their preparation and pharmaceutical compositions comprising the same
10/09/2003WO2003082285A1 Combinations of epinastine, belladonna and pseudoephedrine as new pharmaceutical formulations
10/09/2003WO2003082284A1 Use of desoxynojirimycin and the derivatives thereof for the treatment and prophlaxis of degenerative skin infections
10/09/2003WO2003082283A2 Pharmaceutical composition with combined active agents and methods for using the same
10/09/2003WO2003082282A1 Method of use
10/09/2003WO2003082281A1 Obidoxime dimesylate
10/09/2003WO2003082280A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
10/09/2003WO2003082279A1 Solid preparation containing single crystal form
10/09/2003WO2003082278A1 Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor
10/09/2003WO2003082277A1 Thiazol-2-yl-imine compounds as pde-7 inhibitors
10/09/2003WO2003082276A1 Antidiabetic agents
10/09/2003WO2003082275A1 Treatment of dependence and dependence related withdrawal symptoms
10/09/2003WO2003082274A1 Angiogenesis inhibitors
10/09/2003WO2003082273A1 Solubilization of weak bases
10/09/2003WO2003082272A1 Substituted benzazoles and use thereof as raf kinase inhibitors
10/09/2003WO2003082271A2 Indole derivatives having anti-angiogenetic activity
10/09/2003WO2003082270A1 Method for treating cognitive disorders
10/09/2003WO2003082269A1 Use of statins and other immunomodulatory agents in the treatment of autoimmune disease
10/09/2003WO2003082268A2 Hemiasterlin derivatives and uses thereof in the treatment of cancer
10/09/2003WO2003082267A1 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy
10/09/2003WO2003082266A1 Use of topoisomerase inhibitors and heat shock protein 90 inhibitors for use in chemotherapy
10/09/2003WO2003082264A1 Pharmaceutical composition for preventing or treating respiratory disease
10/09/2003WO2003082263A1 Sulfamic acids as inhibitors of human cytoplasmic protein tyrosine phosphatases
10/09/2003WO2003082262A2 Compositions of venlafaxine base
10/09/2003WO2003082261A1 Extended release venlafaxine formulations
10/09/2003WO2003082260A2 Tuberculosis treatment using pleuromutilin derivatives
10/09/2003WO2003082259A1 Natural phenolic products and derivatives thereof for protection against neurodegenerative diseases
10/09/2003WO2003082258A1 Use of cyr61 for the diagnosis of acute renal failure
10/09/2003WO2003082257A2 Method for treating ocular hypertension and glaucoma
10/09/2003WO2003082256A2 Use of a cb1 cannabinoid receptor antagonist for producing medicaments which are useful for treating sexual behaviour problems and/or for improving sexual performances
10/09/2003WO2003082255A2 Use of mob-5 in pain
10/09/2003WO2003082254A1 Pharmaceutical composition comprising an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male
10/09/2003WO2003082252A1 Hfa-suspension formulations containing an anticholinergic
10/09/2003WO2003082251A2 THE EFFERVESCENT PHARMACEUTICAL DOSAGE FORM OF ESTERS AND ESTER SALTS OF 6 α METHYLPREDNISOLONE SUCCINATE, PROCEDURE FOR ITS OBTAINING AND APPLICATION
10/09/2003WO2003082249A1 Co-beadlet of dha and rosemary and methods of use
10/09/2003WO2003082248A2 Taste masked compositions of erythromycin a and derivatives thereof
10/09/2003WO2003082247A2 Drug microparticles
10/09/2003WO2003082246A1 Stabilized natural cannabinoid formulation
10/09/2003WO2003082245A1 Methods of using lamellar bodies for therapeutic purposes
10/09/2003WO2003082244A2 Hfa-suspension formulation of an anhydrate
10/09/2003WO2003082243A1 Oral suspension formulation
10/09/2003WO2003082241A2 Clarithromycin formulations having improved bioavailability
10/09/2003WO2003082239A1 Use of compatible solutes for inhibiting the release of ceramides
10/09/2003WO2003082233A1 Allyl-phenol compounds in androgenic disorders
10/09/2003WO2003082227A1 Melanogenesis regulator
10/09/2003WO2003082216A2 Neuroprotectant methods, compositions, and screening methods thereof
10/09/2003WO2003082215A2 Synergistic l-methadone compositions and methods of use thereof
10/09/2003WO2003082209A2 Cochleates made with purified soy phosphatidylserine
10/09/2003WO2003082208A2 Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
10/09/2003WO2003082207A2 Volume efficient controlled release dosage form
10/09/2003WO2003082204A2 Sustained-release gel coated compositions
10/09/2003WO2003082199A2 Platelet-activating factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents
10/09/2003WO2003082198A2 Methods of treatment with lxr modulators
10/09/2003WO2003082196A2 Combination therapy using trefoil peptides
10/09/2003WO2003082193A2 Suramin and derivatives thereof as topical microbicide and contraceptive
10/09/2003WO2003082192A2 Certain pharmaceutically useful substituted aminoalkyl heterocycles
10/09/2003WO2003082191A2 Substituted 2,3-diphenyl pyridines
10/09/2003WO2003082190A2 Spirocyclic amides as cannabinoid receptor modulators
10/09/2003WO2003082186A2 Use of benzimidazole analogs in the treatment of cell proliferation
10/09/2003WO2003082139A1 Dispensing apparatus and cartridge
10/09/2003WO2003082081A2 Use of rom production and release inhibitors to treat and prevent intraocular damage
10/09/2003WO2003082011A1 Use of non-antibacterial tetracycline analogs and formulations thereof for the treatment of bacterial exotoxins
10/09/2003WO2003082006A2 Methods and compositions for preventing obesity and obesity related disorders
10/09/2003WO2003057184A3 Hydroxamic acid and its derivatives as inhibitors of melanocyte tyrosinase for topical skin lighteners
10/09/2003WO2003055445A3 Compositions and methods for enhancing corticosteriod delivery
10/09/2003WO2003054208A3 Method of modulating release of saccharides and uses thereof
10/09/2003WO2003052058A3 Dinuclear copper-based compound and ligand for nucleic acid scission and anticancer treatment
10/09/2003WO2003050063A3 PROCESS FOR THE SYNTHESIS OF CHIRALLY PURE β-AMINO-ALCOHOLS
10/09/2003WO2003049804A3 Treatment of genitourinary tract disorders
10/09/2003WO2003045917A3 Ccr-3 receptor antagonists vii
10/09/2003WO2003045466A3 Catheter composition and uses thereof
10/09/2003WO2003045328A3 Methods of making and using theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate and theaflavin 3,3'-digallate and mixtures thereof
10/09/2003WO2003043570A3 Formulations and methods for treatment or amelioration of inflammatory conditions
10/09/2003WO2003040170A3 Antibodies to cd40
10/09/2003WO2003037259A3 Methods for the prevention or treatment of bacterial and fungal infections
10/09/2003WO2003035048A3 Methods for the treatment of osteoarthritis and compositions thereof
10/09/2003WO2003034981A3 Prevention of recurrent viral disease
10/09/2003WO2003026617A3 (ester)-lysolecithins in liposomes
10/09/2003WO2003022994A3 Inhibition by 3-deoxyflavonoids of t-lymphocyte activation and therapies related thereto
10/09/2003WO2003016528A3 Oligonucleotide compositions and their use to induce apoptosis
10/09/2003WO2003013534A3 Methods for the treatment of cancer with irinotecan based on cyp3a5
10/09/2003WO2003013533A3 Methods for improved treatment of cancer with irinotecan based on mrp1
10/09/2003WO2003013270A3 Calcium dietary supplement
10/09/2003WO2003011119A3 Methods and compositions for diagnosis and treatment of vascular conditions
10/09/2003WO2003006893A3 Methods of inhibiting amyloid toxicity
10/09/2003WO2002097075A3 Capping enzyme of flavivirus and utilization of this protein in a process to test drugs with antiviral properties
10/09/2003WO2002087503A3 Compositions and methods for treating colorectal polyps and cancer
10/09/2003WO2002083936A3 Novel method for screening inhibitors of the linkage between the neuronal nitric oxide synthase associated protein and the protein inhibiting neuronal nitric oxide synthase
10/09/2003WO2002083627A3 Ligands des integrins avss6
1 ... 5314 5315 5316 5317 5318 5319 5320 5321 5322 5323 5324 5325 5326 5327 5328 5329 5330 5331 5332 5333 5334 ... 7860